Marion Mateos, Staff Specialist Paediatric Oncology at Sydney Children’s Hospitals Network, shared a post on LinkedIn:
“Thrilled to share the first-in-child results from our Phase 1 clinical trial — The Deflexifol at Relapse Trial (DART), proudly supported by the Kids With Cancer Foundation Australia!
This marks the first time anywhere in the world that this treatment (Deflexifol) has been given to children with Brain Cancer.
About SNO2025
SNO2025 is a prestigious global meeting bringing together leading clinicians and scientists to discuss cutting-edge developments in adult and paediatric BrainCancer research.
Key Findings from the DART Trial
Our trial showed that Deflexifol — a new formulation that packages two anti-cancer agents together (5-fluorouracil 5FU and leucovorin) — was safe and well-tolerated in children.
We also established the safe Phase 2 dose, paving the way to a larger, targeted study focused on ependymoma, a rare and challenging form of BrainCancer requiring urgent treatment.
Thank you to all the patients, families, our incredible funding partners, our trial partners, our sponsor ANZCHOG, the Data Safety Monitoring Committee and my collaborators. We couldn’t have done it without you! Special thank you to Kids With Cancer Foundation Australia and Robert Connor Dawes (RCD) Foundation for your generous funding that has made this trial possible.
I am also the proud recipient of a Robert Connor Dawes (RCD) Foundation travel scholarship to attend this meeting. Thank you also to the The Kids’ Cancer Project who fund my ongoing work through the Col Reynolds Clinical Fellowship.”